AstraZeneca completes equity investment in Summit

AI SummaryClose X

AstraZeneca has completed a $2 billion equity investment in Summit Therapeutics, aiming to accelerate the development of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, for use with antibody drug conjugates across various tumour types. This investment also facilitates a clinical collaboration to evaluate sonesitatug vedotin with ivonescimab and potentially other AstraZeneca cancer medicines. Furthermore, a separate agreement with Daiichi Sankyo will explore combining Datroway with ivonescimab in lung and breast cancers.

Disclaimer*

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings